MedAvant to Extend 10-Q Filing Date and Files for Extension


ATLANTA, May 15, 2008 (PRIME NEWSWIRE) -- MedAvant Healthcare Solutions (MedAvant) (Nasdaq:PILL), a leader in healthcare technology and transaction services, today announced that it needs additional time to finalize its first quarter financial statements and Form 10-Q for the first quarter ended March 31, 2008. Accordingly, it has filed a notification with the Securities and Exchange Commission on Form 12b-25 for the permitted 5-day extension. The Company anticipates that it will file its Form 10-Q on or before May 20, 2008.

About MedAvant Healthcare Solutions

MedAvant is focused on facilitating the exchange of healthcare information so that payers, providers, and patients benefit equally from the sharing of reliable and actionable health data. To enable these services, MedAvant operates Phoenix(sm), a highly scalable platform that supports real-time connections between healthcare clients.

For more information, visit http://www.medavanthealth.com. MedAvant is a trade name of ProxyMed, Inc.

The MedAvant Healthcare Solutions logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3540

Forward Looking Statement

Statements in this release that are "forward-looking statements" are based on current expectations and assumptions that are subject to risks and uncertainties. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. Actual results could differ materially from projected results because of factors such as:



 * The soundness of our business strategies relative to the perceived
   market opportunities;
 * Our ability to successfully develop, market, sell, cross-sell,
   install and upgrade our clinical and financial transaction services
   and applications to current and new physicians, payers and medical
   laboratories;
 * Our ability to satisfy the listing requirements of the Nasdaq
   Global Market or Nasdaq Capital Market;
 * Our ability to compete effectively on price and support services;
 * Our ability and that of our business associates to perform
   satisfactorily under the terms of our contractual obligations, and
   to comply with various government rules regarding healthcare and
   patient privacy;
 * Entry into markets with vigorous competition, market acceptance of
   existing products and services, changes in licensing programs,
   product price discounts, delays in product development and related
   product release schedules, any of which may cause our revenues and
   income to fall short of anticipated levels;
 * The availability of competitive products or services;
 * The continued ability to protect our intellectual property rights;
 * Implementation of operating cost structures that align with revenue
   growth;
 * Uninsured losses;
 * Adverse results in legal disputes;
 * Unanticipated tax liabilities; and
 * The effects of a natural disaster or other catastrophic event
   beyond our control that results in the destruction or disruption of
   any of our critical business or information technology systems.

Any of these factors could cause the actual results to differ materially from the guidance given at this time. For further cautions about the risks of investing in MedAvant, we refer you to the documents MedAvant files from time to time with the Securities and Exchange Commission, including, without limitation, its most recently filed Annual Report on Form 10-K. MedAvant does not assume, and expressly disclaims, any obligation to update information contained in this document. Although this release may remain available on our website or elsewhere, its continued availability does not indicate that we are reaffirming or confirming any of the information contained herein.



            

Contact Data